MedTrace Logo

Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients

NCT05009030 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 794

Last updated 2022-07-29

No results posted yet for this study

Summary

Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography.

This study aims to be nationwide in order to study general common variables of the patients, as well as the correlation with the cancer treatments received.

Conditions

Interventions

DRUG

COVID-19 vaccine

Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities

Sponsors & Collaborators

  • Fundación GECP

    lead OTHER

Principal Investigators

  • Ernest Nadal, MD · Fundación GECP Investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2022-03-28
Completion
2022-03-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05009030 on ClinicalTrials.gov